# Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

> **NCT00370370** · PHASE3 · UNKNOWN · sponsor: **Shahid Beheshti University of Medical Sciences**

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** bevacizumab + triamcinolone acetonide

## Key facts

- **NCT ID:** NCT00370370
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00370370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00370370, "Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00370370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*